Research programme: antibacterials - BioVersys

Drug Profile

Research programme: antibacterials - BioVersys

Alternative Names: BV-6481; TRIC

Latest Information Update: 04 Dec 2014

Price : $50

At a glance

  • Originator BioVersys
  • Developer BioVersys; GlaxoSmithKline; Lille1 University
  • Class Small molecules
  • Mechanism of Action Bacterial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Nosocomial infections; Tuberculosis

Most Recent Events

  • 02 Dec 2014 Preclinical trials in Nosocomial infections in Switzerland (unspecified route) prior to December 2014
  • 02 Dec 2014 Preclinical trials in Tuberculosis in Switzerland (unspecified route) prior to December 2014
  • 27 Jun 2013 Preclinical development is ongoing in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top